-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $36

Benzinga·03/18/2026 16:17:05
Listen to the news
Oppenheimer analyst Jay Olson maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform and lowers the price target from $44 to $36.